| Literature DB >> 25905464 |
Federica Chiappori1, Marco Fumian2, Luciano Milanesi1, Ivan Merelli1.
Abstract
DnaK, the bacterial homolog of human Hsp70, plays an important role in pathogens survival under stress conditions, like antibiotic therapies. This chaperone sequesters protein aggregates accumulated in bacteria during antibiotic treatment reducing the effect of the cure. Although different classes of DnaK inhibitors have been already designed, they present low specificity. DnaK is highly conserved in prokaryotes (identity 50-70%), which encourages the development of a unique inhibitor for many different bacterial strains. We used the DnaK of Acinetobacter baumannii as representative for our analysis, since it is one of the most important opportunistic human pathogens, exhibits a significant drug resistance and it has the ability to survive in hospital environments. The E.coli DnaK was also included in the analysis as reference structure due to its wide diffusion. Unfortunately, bacterial DnaK and human Hsp70 have an elevated sequence similarity. Therefore, we performed a differential analysis of DnaK and Hsp70 residues to identify hot spots in bacterial proteins that are not present in the human homolog, with the aim of characterizing the key pharmacological features necessary to design selective inhibitors for DnaK. Different conformations of DnaK and Hsp70 bound to known inhibitor-peptides for DnaK, and ineffective for Hsp70, have been analysed by molecular dynamics simulations to identify residues displaying stable and selective interactions with these peptides. Results achieved in this work show that there are some residues that can be used to build selective inhibitors for DnaK, which should be ineffective for the human Hsp70.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25905464 PMCID: PMC4408060 DOI: 10.1371/journal.pone.0124563
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Schematic representation of the Hsp70 allosteric cycle.
NBD is in blue, βSBD is in green, helices HA and HB are in yellow and helices HC-HE are in red.
Fig 2Structures and sequences of the five peptides employed in this study.
Atoms are coloured by atom type.
Identity and similarity percentages of DnaK and Hsp70 protein sequences.
|
|
| hHsp70-2 | |
|---|---|---|---|
|
| 100% / 100% | 70% / 80% | 45% / 58% |
|
| 100% / 100% | 45% / 55% | |
| hHsp70-2 | 100% / 100% |
Residues forming hydrogen bonds with the bound peptides.
|
|
| hHsp70 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Api88 | droso | helio | onco | pyrr | Api88 | droso | helio | onco | pyrr | Api88 | droso | helio | onco | pyrr | |
| β1—L1,2 - β2 | - | - | E402 | - | - | - | E402 | E402 | - | - | - | E402 | - | - | - |
| - | - | - | - | - | - | T403 | - | - | - | - | - | T403 | - | T403 | |
|
|
|
|
|
|
| - |
|
|
| A404 | A404 | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | G405 | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | G406 | - | - | - | - | |
| T409 | - | - | - | - | - | - | - | - | - | - | - | T409 | - | - | |
| β3—L3,4 - β4 | - | - | - | - | - | - | - | - | - | - | Q424 | - | - | - | - |
| - | V425 | V425 | - | - | - | V425 | - | - | - | T425 | T425 | - | - | - | |
|
|
|
|
|
|
|
|
|
|
| T427 | T427 | T427 | T427 | T427 | |
|
| - |
|
|
|
|
| - |
|
| - | Y429 | - | - | Y429 | |
| - | - | - | - | - | - | E430 | E430 | E430 | - | - | - | - | S430 | - | |
|
|
|
|
|
|
|
|
|
|
| - | - | - | - | Q433 | |
| - | D437 | D437 | D437 | D437 | T437 | T437 | - | T437 | T437 | - | - | - | - | L437 | |
| HB | - | - | - | - | - | D530 | - | - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | Q534 | - | Q534 | Q534 | - | - | - | - | - | |
| - | N537 | - | N537 | - | - | - | - | - | - | - | - | - | - | - | |
| - | - | - | E538 | - | Q538 | - | Q538 | Q538 | Q538 | - | N538 | N538 | N538 | - | |
| - | D540 | D540 | - | - | - | - | - | - | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | H541 | - | - | E541 | - | - | |
| S544 | - | - | S544 | - | - | - | - | - | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | - | D580 | D580 | - | - | |
| - | - | - | - | Q600 | - | - | - | - | - | - | - | - | - | - | |
Residues involved in interactions conserved in DnaK proteins and not in Hsp70 proteins are underlined.
Residues involved in contacts with the bound peptides.
|
|
| hHsp70 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Api88 | droso | helio | onco | pyrr | Api88 | droso | helio | onco | pyrr | Api88 | droso | helio | onco | pyrr | |
| β1—L1,2 - β2 | - | - | - | - | - | - | - | - | - | - | - | E402 | - | - | - |
| T403 | T403 | T403 | T403 | T403 | T403 | - | T403 | T403 | T403 | T403 | T403 | T403 | T403 | T403 | |
|
|
|
|
| - |
|
|
| - |
| A404 | - | A404 | A404 | - | |
| β3—L3,4 - β4 | - | - | - | - | - | - | - | - | - | - | - | - | Q424 | - | - |
| - | - | V425 | - | - | - | - | - | - | - | - | - | - | - | - | |
| F426 | F426 | F426 | F426 | F426 | F426 | F426 F426 | F426 | F426 | F426 | F426 | F426 | F426 | F426 | F426 | |
|
|
|
|
|
|
|
| - |
|
| - | T427 | - | T427 | - | |
|
|
|
|
|
|
|
|
|
|
| Y429 | Y429 | Y429 | Y429 | Y429 | |
| - | - | - | - | - | - | E430 | E430 | - | - | - | - | - | - | - | |
|
| - | - |
|
|
|
| - |
|
| - | - | - | - | Q433 | |
| - | - | - | - | A435 | A435 | - | - | - | A435 | - | - | - | - | - | |
|
|
| - |
|
|
| - | - |
|
| - | - | - | - | V436 | |
| - | - | D437 | D437 | D437 | - | - | - | T437 | - | - | - | - | - | L437 | |
| HB | P525 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | Q534 | - | Q534 | - | - | - | - | - | - | |
| - | - | - | - | N537 | - | - | - | - | N537 | - | - | - | - | - | |
| - | - | - | - | - | - | Q538 | Q538 | - | - | N538 | N538 | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | A539 | A539 | |
| - | - | - | D540 | - | - | - | - | - | - | - | - | - | - | - | |
| - | - | - | - | - | H541 | - | - | H541 | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | S542 | - | - | S542 | - | |
| - | - | - | - | - | - | - | - | - | - | Y543 | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | - | - | D580 | - | - | |
Residues involved in interactions conserved in DnaK proteins and not in Hsp70 proteins are underlined.
Binding cavity residues.
|
|
| hHsp70 | |
|---|---|---|---|
| β1—L1,2 - β2 |
|
|
|
| β3—L3,4 - β4 |
|
|
|
| L5,6 – β6 | Q458, L459, | N458, |
|
| HB |
| D530, E531, Q534, T535, | V536 (533), A537 (534), |
Residues conserved in all the three proteins are underlined, while residues conserved only in DnaK are bolded.
Fig 3ΔΔGbind results of alanine scanning on binding cavity residues.
Interesting residues are displayed for E.coli, A.baumannii DnaK and human Hsp70 in complex with known inhibitors.
Enthalpic contribution to the binding energy.
| Complex | Key residues | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| M404 | V425 | S427 | A429 | A435 | I438 | G468 | Total | ||
|
|
|
| -4,71 (1%) |
|
| -4,78 (1%) | -9,35 (2%) | -2,60 (0%) | -549,58 |
|
|
| -3,48 (1%) |
|
| -7,97 (2%) | -5,34 (1%) | -2,76 (1%) | -423,19 | |
|
|
|
|
|
| -0,18 (0%) | -3,50 (1%) | -1,25 (0%) | -461,28 | |
|
|
|
| -11,54 (2%) |
| -20,17 (4%) | -10,94 (2%) | -8,37 (2%) | -1,40 (0%) | -529,30 |
|
|
| -2,43 (0%) |
| -14,34 (3%) | -11,01 (2%) | -3,63 (1%) | 0,60 (0%) | -513,29 | |
|
| -4,91 (1%) | -12,26 (3%) |
|
|
| 1,49 (0%) | -2,74 (1%) | -472,37 | |
|
|
| -26,25 (4%) | -26,73 (4%) |
| -24,01 (4%) | -13,32 (2%) | -3,03 (0%) | 1,03 (0%) | -623,49 |
|
| -8,27 (1%) | -12,82 (2%) |
| -24,36 (4%) | -5,93 (1%) | -4,62 (1%) | 7,25 (-1%) | -627,85 | |
|
| -12,83 (2%) | -0,22 (0%) | -25,97 (3%) | -30,43 (4%) | -0,08 (0%) | -1,60 (0%) | 0,00 (0%) | -819,03 | |
|
|
| -20,96 (4%) | -12,98 (3%) |
|
| -6,54 (1%) | -0,76 (0%) | -0,66 (0%) | -485,95 |
|
| -20,00 (4%) | -11,00 (2%) |
| -18,39 (4%) | -8,84 (2%) | 0,38 (0%) | -2,89 (1%) | -464,65 | |
|
| -22,42 (4%) | -10,15 (2%) |
|
| -1,18 (0%) | -8,54 (2%) | -7,33 (1%) | -500,45 | |
|
|
| -19,10 (4%) | -8,29 (2%) |
|
| -9,45 (2%) | -7,44 (2%) | -6,20 (1%) | -487,61 |
|
|
| -3,07 (1%) |
|
| -6,98 (2%) | -6,25 (1%) | -2,38 (1%) | -458,42 | |
|
| -6,84 (2%) | -12,61 (3%) |
|
| -9,49 (2%) | -5,98 (1%) | -0,37 (0%) | -434,77 | |
Energetic contribution to the ligand interaction of residues in the binding cavity. The percentage of each residue contribution to the total enthalpy is indicated in brackets. The more relevant values are highlighted in italic.
Fig 4WebLogo representation obtained from the alignment of the 65 DnaK (a) and of the 13 human Hsp70 (b) sequences.
Residues belonging to the binding site are underlined, residues identified with alanine scanning analysis are in red boxes, residues obtained by interaction analysis are in blue boxes and residues identified in the pharmacophoric analysis are in green boxes. Residues double underlined are identified hot spots.
Fig 5Structure-based pharmacophore.
Pharmacophore built on residues important for the interaction between DnaK and inhibitor-peptides and not identified in human proteins. The yellow spheres represent the hydrophobic groups, red and green arrows identify, respectively, H-bonds acceptors and donors. Red and blue spheres are, respectively, negative and positive ionizable groups.
Fig 6Key residues identified in DnaK SBD.
Residue side-chains are in ball and stick, Cα atoms of residues previously exploited by known inhibitors are in light blue, Cα of the new identified hot spot residues are in orange. The Api88 peptide is represented in red.